{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:33:46Z","timestamp":1753882426394,"version":"3.41.2"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,30]],"date-time":"2006-01-30T00:00:00Z","timestamp":1138579200000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases in Obstetrics and Gynecology"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:p>Human papillomavirus (HPV), a sexually transmitted infection and\nthe etiologic cause of genital warts and cervical cancer, is\nhighly prevalent in sexually active men and women. Although\ncervical screening procedures have significantly reduced the\ndisease burden associated with HPV infection, they are expensive\nand abnormal results cause significant emotional distress.\nTherefore, prevention may be an effective strategy for reducing\nthe economic, psychosocial, and disease burden of HPV infection.\nMultivalent vaccines are now in clinical development. A bivalent\nvaccine that protects against HPV 16 and 18, and a quadrivalent\nvaccine which protects against HPV types 6, 11, 16, and 18, have\nbeen shown to significantly reduce the occurrence of incident and\npersistent HPV infections in phase 2 clinical trials; phase 3\ntrials are currently underway. HPV vaccines will be most effective\nwhen administered prior to initiation of sexual activity, and\nvaccination campaigns should aggressively target preadolescent and\nadolescent populations.<\/jats:p>","DOI":"10.1155\/idog\/2006\/83084","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T12:33:36Z","timestamp":1150893216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reducing the Health Burden of HPV Infection Through Vaccination"],"prefix":"10.1155","volume":"2006","author":[{"given":"David","family":"Soper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,30]]},"reference":[{"key":"e_1_2_1_1_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00007435-199904001-00002","article-title":"Estimates of the incidence and prevalence of sexually transmitted diseases in the United States.\n    American Social Health Association Panel","volume":"26","author":"Cates","year":"1999","journal-title":"Sexually Transmitted Diseases"},{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1363\/3600604"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199607000-00013"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/320696"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.10.3316-3322.1999"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036020"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.5.245"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.14.997"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802123380703"},{"key":"e_1_2_1_12_2","first-page":"421","article-title":"Incidence, clearance and predictors of human papillomavirus infection in women","volume":"168","author":"Sellors J W","year":"2003","journal-title":"CMAJ: Canadian Medical Association Journal"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.4.679"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200211000-00018"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11474"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.01.042"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1363\/3601104"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90772-4"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.1.315-322.1993"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro867"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11553"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00103-8"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0702"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg018"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.4.284"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020586"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/323645"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.02.020"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.058"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","unstructured":"SkjeldestadF E FUTURE II steering committee. Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6 11 16 18) L1 Virus-Like Particle (VLP) Vaccine (Gardasil) Reduces Cervical Intraepithelial Neoplasia (CIN) 2\/3 Risk Infectious Disease Society of America 43rd Annual Meeting 2005 San Francisco Calif Abstract LB-8a. Available at:https:\/\/www.idsociety.org\/Template.cfm?Section=Program2&CONTENTID=14108&TEMPLATE=\/ContentManagement\/ContentDisplay.cfm . Accessed at: January 16 2006.","DOI":"10.1016\/S1359-6349(05)82013-0"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0901.020168"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1011.040222"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200211000-00006"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005192902137"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.17.1.26"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/her\/17.6.706"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(00)01009-7"}],"container-title":["Infectious Diseases in Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/idog\/2006\/083084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/IDOG\/2006\/83084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:07:05Z","timestamp":1717704425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/IDOG\/2006\/83084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1155\/IDOG\/2006\/83084"],"URL":"https:\/\/doi.org\/10.1155\/idog\/2006\/83084","archive":["Portico"],"relation":{},"ISSN":["1064-7449"],"issn-type":[{"type":"print","value":"1064-7449"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"2006-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"083084"}}